Walgreens Boots Alliance has announced the launch of its new clinical trials business that aims to use patient data from its pharmacies to help drive up
recruitment in studies conducted by drugmakers.
With patient recruitment and enrollment remain key challenges in clinical trials, further exacerbated by the COVID-19 pandemic, the company said it can proactively
match diverse patient populations to trials across a range of disease areas based on race, gender, socioeconomic status and location with its patient reach and
access to an extensive foundation of pharmacy and patient-authorised clinical data.
The Boots owner also believes that by leveraging a tech-enabled approach to patient identification and creating a large registry of clinical trial participants,
the company will be able to reduce the time it takes to match eligible patients to clinical trials.
"Walgreens trusted community presence across the nation, combined with our enterprise-wide data and health capabilities, enables us to pioneer a comprehensive
solution that makes health options, including clinical trials, more accessible, convenient and equitable," said Ramita Tandon, chief clinical trials officer,
Walgreens.